Response to article by Matthew Wasserman et al. (2018): “Modeling the sustained use of the 13-valent pneumococcal conjugate vaccine compared to switching to the 10-valent vaccine in Mexico”

In a recent article, Wasserman et al. estimated and forecasted the health and economic impact of switching from the 13-valent (PCV-13) to the 10-valent (PHiD-CV) pneumococcal conjugate vaccine in Mexico’s national immunization program. In this response letter, we highlight various methodological inc...

Descripción completa

Detalles Bibliográficos
Autores principales: Gómez, Jorge A., Guzman Holst, Adriana, Nieto, Javier
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2018
Materias:
Reply Letter
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6988871/
https://www.ncbi.nlm.nih.gov/pubmed/30570428
http://dx.doi.org/10.1080/21645515.2018.1554974
_version_ 1783492325430788096
author Gómez, Jorge A.
Guzman Holst, Adriana
Nieto, Javier
author_facet Gómez, Jorge A.
Guzman Holst, Adriana
Nieto, Javier
author_sort Gómez, Jorge A.
collection PubMed
description In a recent article, Wasserman et al. estimated and forecasted the health and economic impact of switching from the 13-valent (PCV-13) to the 10-valent (PHiD-CV) pneumococcal conjugate vaccine in Mexico’s national immunization program. In this response letter, we highlight various methodological inconsistencies and model input considerations that potentially bias the results and further recommendations made by the authors.
format Online
Article
Text
id pubmed-6988871
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Taylor & Francis
record_format MEDLINE/PubMed
spelling pubmed-69888712020-02-14 Response to article by Matthew Wasserman et al. (2018): “Modeling the sustained use of the 13-valent pneumococcal conjugate vaccine compared to switching to the 10-valent vaccine in Mexico” Gómez, Jorge A. Guzman Holst, Adriana Nieto, Javier Hum Vaccin Immunother Reply Letter In a recent article, Wasserman et al. estimated and forecasted the health and economic impact of switching from the 13-valent (PCV-13) to the 10-valent (PHiD-CV) pneumococcal conjugate vaccine in Mexico’s national immunization program. In this response letter, we highlight various methodological inconsistencies and model input considerations that potentially bias the results and further recommendations made by the authors. Taylor & Francis 2018-12-20 /pmc/articles/PMC6988871/ /pubmed/30570428 http://dx.doi.org/10.1080/21645515.2018.1554974 Text en © 2018 GlaxoSmithKline Biologicals SA. Published with license by Taylor & Francis Group, LLC http://creativecommons.org/licenses/by/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Reply Letter
Gómez, Jorge A.
Guzman Holst, Adriana
Nieto, Javier
Response to article by Matthew Wasserman et al. (2018): “Modeling the sustained use of the 13-valent pneumococcal conjugate vaccine compared to switching to the 10-valent vaccine in Mexico”
title Response to article by Matthew Wasserman et al. (2018): “Modeling the sustained use of the 13-valent pneumococcal conjugate vaccine compared to switching to the 10-valent vaccine in Mexico”
title_full Response to article by Matthew Wasserman et al. (2018): “Modeling the sustained use of the 13-valent pneumococcal conjugate vaccine compared to switching to the 10-valent vaccine in Mexico”
title_fullStr Response to article by Matthew Wasserman et al. (2018): “Modeling the sustained use of the 13-valent pneumococcal conjugate vaccine compared to switching to the 10-valent vaccine in Mexico”
title_full_unstemmed Response to article by Matthew Wasserman et al. (2018): “Modeling the sustained use of the 13-valent pneumococcal conjugate vaccine compared to switching to the 10-valent vaccine in Mexico”
title_short Response to article by Matthew Wasserman et al. (2018): “Modeling the sustained use of the 13-valent pneumococcal conjugate vaccine compared to switching to the 10-valent vaccine in Mexico”
title_sort response to article by matthew wasserman et al. (2018): “modeling the sustained use of the 13-valent pneumococcal conjugate vaccine compared to switching to the 10-valent vaccine in mexico”
topic Reply Letter
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6988871/
https://www.ncbi.nlm.nih.gov/pubmed/30570428
http://dx.doi.org/10.1080/21645515.2018.1554974
work_keys_str_mv AT gomezjorgea responsetoarticlebymatthewwassermanetal2018modelingthesustaineduseofthe13valentpneumococcalconjugatevaccinecomparedtoswitchingtothe10valentvaccineinmexico
AT guzmanholstadriana responsetoarticlebymatthewwassermanetal2018modelingthesustaineduseofthe13valentpneumococcalconjugatevaccinecomparedtoswitchingtothe10valentvaccineinmexico
AT nietojavier responsetoarticlebymatthewwassermanetal2018modelingthesustaineduseofthe13valentpneumococcalconjugatevaccinecomparedtoswitchingtothe10valentvaccineinmexico

Ejemplares similares